Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Who is being left behind? – herald Tawanda Musarurwa Check Point Desk “EVEN when people know about HIV and take risks, there are still many reasons why some men might not go for testing. “Sometimes it ...

SPMC Chief Dr. Ricardo Audan addressed a complaint from an LGBTQ+ ally regarding his remarks linking Mpox infections in HIV-positive individuals to "high-risk activities." He clarified the statement ...

UNAIDS Executive Director Winnie Byanyima has raised the alarm over a potential surge in HIV infections among key populations ...

Scientists at Mass General Brigham have developed a powerful new tool called LUCAS (Luminescence CAscade-based Sensor).

The fund, an independent partnership where money mainly comes from public sector donors, plans to raise at least $18 billion ...

This is a Premium Article, available exclusively to our subscribers. Read 500+ such articles every month by subscribing today ...

Other Harvard-backed projects facing funding cuts include research on tuberculosis and early detection of Lou Gehrig’s ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Goldman Sachs analyst ...

Botswana’s Bold Move Ends HIV Transmission from Mothers to Children ...

The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the ...

The director of the Africa CDC believes the abrupt cutoff of Western aid will cause great suffering to Africans. At the same ...